This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Advance Auto Parts(AAP) upgraded at JP Morgan to overweight, JP Morgan said. Company can gain market share in an industry that's likely to see a soft landing in 2013.
Aecom(ACM) upgraded at BofA/Merrill from underperform to buy, Bank of America/Merrill Lynch said. $35 price target. Company is seeing a solid recovery in free cash flow.
Activision Blizzard(ATVI - Get Report) upgraded at Sterne Agee from neutral to buy, Sterne Agee said. $17 price target. Company is positioned well for the next business cycle and the company will likely buy back a significant amount of shares.
Biogen Idec(BIIB - Get Report) upgraded at Citigroup to buy from neutral, Citigroup said. $187 price target. Expecting a solid Tecfidera launch.
Celgene(CELG) rated new outperform at JMP. $130 price target. Company is a market leader and can continue to deliver solid growth.
Discover(DFS) upgraded at Credit Suisse from neutral to outperform, Credit Suisse said. $47 price target. Company can deliver the best growth in the industry at the lowest valuation.
DSW(DSW) rated new buy at Sterne Agee. $75 price target. Company is a market leader and can deliver above-average growth for the foreseeable future.
Guess(GES) upgraded at Wedbush from neutral to outperform, Wedbush said. $34 price target. There are early signs that the business is turning around in North America.
Gartner(IT) downgraded at Piper from overweight to neutral, Piper Jaffray said. Valuation call, based on a $52 price target.
Annaly Capital(NLY) upgraded at Sterne Agee from underperform to neutral, Sterne Agee said. Valuation call, based on a $14.25 price target.
Nuance(NUAN) downgraded at Needham from buy to hold, Needham said. Company is seeing lower international sales and demand from healthcare customers.
MetroPCS(PCS) upgraded at Nomura from reduce to neutral, Nomura said. $9.50 price target. Worst news appears to be behind the company.
Riverbed(RVBD) downgraded at FBR from outperform to market perform, FBR Capital Markets said. $20 price target. Company is seeing lower core sales.